Previous Article | Next Article ![]()
Appl. Environ. Microbiol., Oct 1995, 3544-3548, Vol 61, No. 10
A Shafiee, T Chen and P Cameron
As a result of an extensive screening program for the microbial
modification of the immunosuppressant FK-506, one culture, Streptomyces
rimosus MA187, which specifically catalyzed the C-31 demethylation of
FK-506 was identified. Treatment of the biotransforming culture with FK-506
increased demethylase activity 2.4-fold and stabilized the cytochrome P-450
protein. The enzyme responsible for this demethylation (31-O-FK-506
demethylase) was isolated and shown to be a soluble cytoplasmic protein
which is constitutively expressed in the cells, which requires NADPH,
ferredoxin-NADP(sup+)-reductase, and ferredoxin for activity, and which
shows a cytochrome P-450 light absorption characteristic. Carbon monoxide
saturation of the enzyme preparation and known mammalian cytochrome P-450
inhibitors such as quinidine HCl, ketoconazole, troleandomycin, and
sulfaphenazole abolish the demethylating activity extensively. The purified
enzyme is a monomeric protein with a molecular mass of 42 kDa and shows its
maximal activity at a pH of 7.4 and an incubation temperature of 34(deg)C.
The first 19 N-terminal amino acids in the sequence of the purified protein
have been determined, with no cytochrome P-450 match found in the OWL and
Swiss-Prot 23 databases. The isolated demethylase is therefore a cytochrome
P-450 protein that can be used as a catalyst for the synthesis of
31-O-desmethylFK-506, an important immunosuppressant and a known metabolite
of FK-506 metabolism by human liver microsomes.
Copyright © 1995, American Society for Microbiology
Microbial Demethylation of Immunosuppressant FK-506: Isolation of 31-O-FK-506-Specific Demethylase Showing Cytochrome P-450 Characteristics from Streptomyces rimosus MA187
Merck Research Laboratories, Rahway, New Jersey 07065
This article has been cited by other articles:
| J. Bacteriol. | Microbiol. Mol. Biol. Rev. | Eukaryot. Cell | All ASM Journals |
|---|